Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Pancreatic islet adaptation is vital for metabolic balance, but underlying mechanisms remain unclear.
• Calcineurin/NFAT signaling is implicated in adaptive islet responses, yet its role in beta-cells in vivo is unknown.
• Cyclosporin A treatment in diabetic patients suggests a link between calcineurin inhibitors and islet function.

Purpose of the Study:

• To investigate the role of calcineurin/NFAT signaling in beta-cell adaptation and function in vivo.
• To determine the impact of calcineurin b1 deletion in beta-cells on diabetes development.
• To explore the therapeutic potential of modulating NFAT activity in beta-cells.

Main Methods:

• Generated mice with beta-cell-specific deletion of calcineurin b1 (Cnb1).
• Assessed beta-cell proliferation, mass, insulin content, and glucose homeostasis.
• Utilized conditional expression of active NFATc1 to rescue defects in Cnb1-deficient beta-cells.

Main Results:

• Beta-cell-specific Cnb1 deletion led to age-dependent diabetes with reduced beta-cell proliferation, mass, and insulin content.
• Cnb1-deficient beta-cells showed decreased expression of proliferation regulators.
• Conditional NFAT activation rescued these defects and increased beta-cell proliferation, mass, and insulin production.

Conclusions:

• Calcineurin/NFAT signaling is essential for regulating beta-cell growth, mass, and function.
• This pathway controls key genes involved in beta-cell endocrine function and proliferation.
• Modulating calcineurin/NFAT signaling presents a novel therapeutic strategy for diabetes.